Abstract
Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Current Medicinal Chemistry
Title: Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Volume: 11 Issue: 3
Author(s): C. Simon Sebastian, William Glazer and Peter F. Buckley
Affiliation:
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Abstract: Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Export Options
About this article
Cite this article as:
Sebastian Simon C., Glazer William and Buckley F. Peter, Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia, Current Medicinal Chemistry 2004; 11 (3) . https://dx.doi.org/10.2174/0929867043456025
DOI https://dx.doi.org/10.2174/0929867043456025 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotics in Obsessive-Compulsive Disorder
Current Psychiatry Reviews Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Targeted D4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development
Current Drug Targets Risk Factors and Metabolism of Different Brain Regions by Positron Emission Tomography in Parkinson Disease with Disabling Dyskinesia
Current Neurovascular Research Nitric Oxide Production during Cerebral Ischemia and Reperfusion in eNOS- and nNOS-Knockout Mice
Current Neurovascular Research Sepsis-induced Cardiomyopathy
Current Cardiology Reviews 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Genotyping as a Tool to Predict Adverse Drug Reactions
Current Topics in Medicinal Chemistry Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic outpatients Taking Different Antipsychotic Regimens
Current Drug Safety L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Review of Recent Patents on Wearable Movement Sensors
Recent Patents on Biomedical Engineering (Discontinued) Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets